BPTS

Biophytis SA [BPTS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

BPTS Stock Summary

Top 10 Correlated ETFs

BPTS


Top 10 Correlated Stocks

BPTS


In the News

08:42 22 Mar 2023 BPTS

Why Is Biophytis (BPTS) Stock Up 28% Today?

Biophytis (NASDAQ: BPTS ) stock is taking off on Thursday after the company revealed results from a recent clinical trial. The big news affecting BPTS stock today comes from a Phase 2/3 study of Sarconeos as a treatment for severe respiratory failure in patients suffering from Covid-19.

02:20 22 Mar 2023 BPTS

Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 9, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023. Professor Suzana Lobo, MD -Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São Paulo, Brazil and Investigator of the COVA study in Brazil, will be holding an oralpresentation of the results titled "COVA clinical study:Results from a double-blind, placebo-controlled phase2/3 study to assess efficacy and safety of BIO101 in hospitalized severe COVID-19 patients.

10:02 22 Mar 2023 BPTS

5 Penny Stocks To Watch With Big News This Week

Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

08:01 22 Mar 2023 BPTS

Why Is Biophytis (BPTS) Stock Up 42% Today?

Biophytis (NASDAQ: BPTS ) stock is rocketing higher on Thursday after the company signed a master service agreement with Intsel Chimos. With this agreement, Intsel Chimos will become the Pharmaceutical Operator/Exploitant in France for Sarconeos.

08:15 22 Mar 2023 BPTS

Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022

Biophytis SA (NASDAQ: BPTS) said that it is currently assessing FDA comments and recommendations and preparing to submit Phase 2-3 trial designs for sarconeos (BIO101) trial in sarcopenia. Enrollment is expected to start in 2H of 2022 in the SARA Phase 2 trial.

09:03 22 Mar 2023 BPTS

Why Are Biophytis Shares Trading Higher During Premarket Trading?

Biophytis SA BPTS has received approval from the ANVISA (Brazilian health authority) for its Expanded Access Program (EAP) to treat hospitalized patients with severe COVID-19 with Sarconeos (BIO101).  Thousands of new traders are learning the ins and outs on how to find profitable trades every day with Benzinga Trading School.

02:55 22 Mar 2023 BPTS

Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 29, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today reports the restated financial statements as per the Company's previous announcement on October 7, 2021 for the periods ending December 31, 2019, December 31 2020, June 30 2020 and June 30 2021, with no impact on the Company's cash and cash equivalent as of June 30 2021. 1/ Preliminary remarks Pursuant to the provisions of IAS 8, the Company determined following the review by and discussions with the Company's independent registered public accounting firm, that it is necessary to restate the Company's previously issued consolidated financial statements for the 2019 and 2020 financial years and for the first semester of the financial years 2020 and 2021, in order to make certain corrections required to reflect the proper accounting treatment of the Company's convertible notes.

05:00 22 Mar 2023 BPTS

Biophytis to Restate Previously Issued Financial Statements

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced that the Company's previously issued audited consolidated financial statements for the fiscal years ended December 31, 2019 and 2020 and unaudited consolidated financial statements for the six month periods ended June 30, 2021 and 2020 will be restated to correct the Company's accounting treatment of its convertible notes.

02:00 22 Mar 2023 BPTS

Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia.

05:00 22 Mar 2023 BPTS

Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million

PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the issuance of 240 Bonds Redeemable in Cash and New and Existing Shares (ORNANE) for a total amount of €6 million under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York (United States) for €24 million (the "2020 Atlas Contract").

BPTS Financial details

Company Rating
-
Market Cap
10.68M
Income
-18.73M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
26
Optionable
No
Shortable
Yes
Earnings
20 Apr 2023
P/E
-0.16
Forward P/E
-
PEG
-0
P/S
-
P/B
0.85
P/C
-
P/FCF
-0.5
Quick Ratio
1.31
Current Ratio
1.37
Debt / Equity
5.33
LT Debt / Equity
1.1
-
-
EPS (TTM)
-13.94
EPS next Y
-
EPS next Q
-
EPS this Y
-7.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-19.73%
-
-
-
-
SMA20
15.91%
SMA50
18.6%
SMA100
-7.27%
Inst Own
0.08%
Inst Trans
0.02%
ROA
-86%
ROE
-496%
ROC
-2.04%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
29.52M
Shs Float
14.52M
-
-
-
-
Target Price
-
52W Range
0.35-3.36
52W High
-
52W Low
-
RSI
43.25
Rel Volume
0.12
Avg Volume
848.96K
Volume
100.08K
Perf Week
-24.69%
Perf Month
-32.72%
Perf Quarter
-29.31%
Perf Half Y
-42.32%
-
-
-
-
Beta
1.18336
-
-
Volatility
0.07%, 0.07%
Prev Close
14%
Price
0.4105
Change
-6.28%

BPTS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
Revenue per share
00000
Net income per share
-12.42-10.39-10.54-2.84-2.64
Operating cash flow per share
-9.5-8.96-9.050-2.01
Free cash flow per share
-9.64-9.04-9.210-2.04
Cash per share
21.6110.74.033.132.13
Book value per share
23.095.23-4.441.140.49
Tangible book value per share
20.873.79-5.880.690.25
Share holders equity per share
23.095.23-4.441.140.49
Interest debt per share
4.696.2310.532.251.67
Market cap
12.62M19.4M24.87M81.31M55.77M
Enterprise value
-6.23M13.2M33.77M84.56M47.22M
P/E ratio
-1.11-1.39-1.4-4.77-1.78
Price to sales ratio
00000
POCF ratio
-1.45-1.61-1.630-2.34
PFCF ratio
-1.42-1.59-1.60-2.31
P/B Ratio
0.592.76-3.3211.859.72
PTB ratio
0.592.76-3.3211.859.72
EV to sales
00000
Enterprise value over EBITDA
0.79-0.97-2.25-6.82-1.78
EV to operating cash flow
0.71-1.09-2.210-1.98
EV to free cash flow
0.7-1.08-2.170-1.96
Earnings yield
-0.9-0.72-0.72-0.21-0.56
Free cash flow yield
-0.7-0.63-0.630-0.43
Debt to equity
0.222.11-3.362.975.33
Debt to assets
0.180.681.430.750.84
Net debt to EBITDA
2.380.45-0.59-0.260.32
Current ratio
5.952.340.751.311.37
Interest coverage
-3.01-74.92-6.21-3.19-6.05
Income quality
0.760.860.8600.76
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.080.090.140.10.08
Capex to operating cash flow
0.010.010.0200.01
Capex to revenue
00000
Capex to depreciation
-0.63-0.5-1.080-1.11
Stock based compensation to revenue
00000
Graham number
80.3234.9532.448.565.37
ROIC
0.611.175.46-1.851.4
Return on tangible assets
-0.48-0.7-1.16-0.7-0.93
Graham Net
19.152.28-7.40.38-0.13
Working capital
19.5M11.07M-4.95M5.65M8.55M
Tangible asset value
19.18M5.1M-9.93M4.16M2.95M
Net current asset value
18.67M4.5M-10.49M3.63M1.13M
Invested capital
0.051.17-2.031.332.68
Average receivables
1.66M4.01M6.27M6.53M5.16M
Average payables
2.16M3.63M6.37M7.93M7.8M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.54-1.992.37-2.48-5.45
Capex per share
-0.14-0.08-0.170-0.03

Quarterly Fundamentals Overview

Last date of statement is 2021-12-31 for Q4

Metric History 2019-06-302020-06-302020-12-312021-06-30 2021-12-31
Revenue per share
00000
Net income per share
-4.81-3.51-2.8200
Operating cash flow per share
-3.960000
Free cash flow per share
-4.160000
Cash per share
3.879.2413.9400
Book value per share
-1.93-3.275.100
Tangible book value per share
-3.66-5.223.0900
Share holders equity per share
-1.93-3.275.100
Interest debt per share
7.887.576.4700
Market cap
19.69M19.72M18.25M00
Enterprise value
24.78M18.89M21.5M-8.4M-8.55M
P/E ratio
-0.76-1.04-1.200
Price to sales ratio
00000
POCF ratio
-3.70000
PFCF ratio
-3.520000
P/B Ratio
-7.57-4.482.6600
PTB ratio
-7.57-4.482.6600
EV to sales
00000
Enterprise value over EBITDA
-4.06-3.24-5.1400
EV to operating cash flow
-4.650000
EV to free cash flow
-4.420000
Earnings yield
-0.33-0.24-0.2100
Free cash flow yield
-0.280000
Debt to equity
-6.71-5.292.974.965.33
Debt to assets
1.181.240.750.830.84
Net debt to EBITDA
-0.830.14-0.7800
Current ratio
1.150.811.311.151.37
Interest coverage
-19.863.28.3100
Income quality
0.820000
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.150.140.10.070.08
Capex to operating cash flow
0.050000
Capex to revenue
00000
Capex to depreciation
-4.07-0.01000
Stock based compensation to revenue
00000
Graham number
14.4516.0817.9900
ROIC
7.390.25-0.4300
Return on tangible assets
-0.52-0.29-0.1500
Graham Net
-5.42-6.221.7100
Working capital
1.54M-3.66M5.65M4.2M8.55M
Tangible asset value
-4.93M-7.02M4.16M3.39M2.95M
Net current asset value
-5.56M-7.53M3.63M2.86M1.13M
Invested capital
-3.96-2.581.332.432.68
Average receivables
6.13M0000
Average payables
4.99M0000
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
2.491.07-0.5500
Capex per share
-0.20000

BPTS Frequently Asked Questions

What is Biophytis SA stock symbol ?

Biophytis SA is a FR stock and trading under the symbol BPTS

What is Biophytis SA stock quote today ?

Biophytis SA stock price is $0.4105 today.

Is Biophytis SA stock public?

Yes, Biophytis SA is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap